Abstracts tagged "Systemic sclerosis"

Abstract Number: 0630 • ACR Convergence 2023
Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry
Marissa Savoie¹, Monica Harding², Jessica Alvey², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Laura Hummers¹⁰, Dinesh Khanna¹¹, Kimberly Lakin⁸, Dorota Lebiedz-Odrobina¹², Yiming Luo¹³, Ashima Makol¹⁴, Jerry Molitor¹⁵, Duncan Moore¹⁶, Carrie Richardson¹⁷, Nora Sandorfi¹⁸, Ami Shah¹⁹, Ankoor Shah²⁰, Brian Skaug²¹, Virginia Steen²², Elizabeth Volkmann²³ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹University of Michigan, Ann Arbor, MI, ¹²University of Utah, Cottonwood Heights, UT, ¹³Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁴Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶Northwestern University, Department of Rheumatology, Chicago, IL, ¹⁷Northwestern University, Chicago, IL, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²⁰Duke University, Durham, NC, ²¹Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²²Georgetown University School of Medicine, Washington, DC, ²³University of California Los Angeles, Los Angeles, CA
Background/Purpose: Digital ischemic ulcers (DIU) develop in 36-44% of patients with systemic sclerosis (SSc).1,2Prior international observational studies have evaluated characteristics of digital pitting and ulcers…
Abstract Number: 0651 • ACR Convergence 2023
Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry
Jesus Loarce-Martos¹, Hilda Godoy², Laura Cebrian³, M Jesus Rodriguez-Nieto⁴, Juan Rigual⁵, Rosalía Laporta², Belen Lopez-Muñiz³, lydia Abasolo⁶, Olga Sanchez Pernaute⁷ and Fredeswinda Romero⁷, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ⁵Pulmonology department, Hospital Ramón y Cajal,, Madrid, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷IIS-HU Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The aim of this study is to describe the nailfold video-capillaroscopy (NVC) findings in patients with interstitial lung disease associated to connective tissue diseases…
Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Jule Taubmann¹, Fabian Müller², Michael Aigner³, Ioanna Minopoulou⁴, Johannes Knitza⁵, Dagmar Werner⁶, Christina Bergmann⁷, Gerhard Kroenke⁸, Andreas Mackensen³ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁸Charite Berlin, Berlin, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
Abstract Number: 0947 • ACR Convergence 2023
Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis
Amela Hukara¹, Gino Andrea Bonazza¹, Tracy Tabib², Raphael Micheroli¹, Suzana Jordan³, Kristina Bürki¹, Sylvie Schlitz Schönbächler¹, Adrian Ciurea⁴, Oliver Distler³, Robert Lafyatis⁵, Przemyslaw Blyszczuk¹ and Gabriela Kania¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Fcy receptors (FcγR) are opsonic phagocytic receptors, requiring tight regulations to prevent uncontrolled activation of pro-inflammatory phagocytosis. SSc macrophages display an alternatively-activated profibrotic phenotype.…
Abstract Number: 1513 • ACR Convergence 2023
Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019
Anum Akhlaq¹, Emily He² and Risha Fayyaz³, ¹University of Mississippi Medical Center, Jackson, MS, ²Loma Linda University Health, Loma Linda, CA, ³University of Mississippi Medical Center, Flowood, MS
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic disease characterized by widespread vascular damage and tissue fibrosis of the skin and various internal organs, which…
Abstract Number: 1667 • ACR Convergence 2023
Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry
Minrui Liang¹, Aleix Rius Rigau², yi-nan Li¹ and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie (DZI), FAU Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a prototypical collagen-vascular disease with prominent vasculopathy. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular dysregulation…
Abstract Number: 2360 • ACR Convergence 2023
Systemic Sclerosis Macrophages Stimulate Calcinosis in Adipose Derived Mesenchymal Stem Cells via the Activin a Pathway
Tamara Searle¹, Ujvalla Kalluri¹, Sonia Ahmad², Bahja Ahmed Abdi¹, Sandra Lopez¹, Shiwen Xu¹, Teresa Collins¹, Jennifer Cross³, George Martin⁴, Henry Lopez⁵, Clayton Yates⁶ and Richard Stratton¹, ¹University College London, London, United Kingdom, ²Holy Family Red Crescent Medical College, Dhaka, Bangladesh, ³Aurinia Pharmaceuticals Inc., Rockford, MD, ⁴Riptide Bioscience Inc., Bethesda, MD, ⁵Riptide Bioscience Inc., Valejo, CA, ⁶Tuskegee University, Tuskegee, AL
Background/Purpose: Calcinosis may result from localised trans-differentiation of tissue resident stem cells in the subcutaneous layer of affected skin in systemic sclerosis (SSc), as a…
Abstract Number: 0613 • ACR Convergence 2023
Quantification of Skin Hardness of Patients with Systemic Sclerosis Using SOFTGRAM
Hiraku Kokubu¹, Yasuaki Ikuno¹, Kazuyuki Uchiyama¹, Miwa Kato¹, Mayuka Yamamoto¹, Haruki Asada¹, Satona Rikitake¹, Yoshimichi Kobayashi¹, Takahiro Koike¹, Syuji Sugiura¹, Takuma Hayami¹, Kensuke Yoneta¹, Toshifumi Takahashi¹, Bunpei Yamamoto¹, Takeshi Kato¹, Yoshito Kunisaki², Makoto Nakatani², Kohei Okamoto² and Noriki Fujimoto¹, ¹Shiga University of Medical Science, Otsu, Japan, ²ISHIDA MEDICAL CO.,LTD., Kyoto, Japan
Background/Purpose: No quantitative and objective methods for measuring skin hardness have been established. Japanese technology leads the world in the tactile sensor field, and SOFTGRAM…
Abstract Number: 0631 • ACR Convergence 2023
Safety of Radiotherapy for Malignancy in Systemic Sclerosis. a Systematic Review
Aos Aboabat¹, Mohammed AlDohan², Patrick Cheung², Ani Orchanian-Cheff³ and Sindhu Johnson⁴, ¹University of Toronto, Toronto, ON, Canada, ²Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ³Library and Information Services, University Health Network, Toronto, ON, Canada, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with higher risks of malignancies. Concerns regarding offering radiotherapy (RT) to SSc patients stem from the…
Abstract Number: 0653 • ACR Convergence 2023
Association Between Systemic Sclerosis and Increased Risk of Ischemic Stroke: A Meta-Analysis
Christina Flourou¹, Andreas Liampas¹ and Konstantinos Parperis², ¹Nicosia General Hospital, Nicosia, Cyprus, ²University of Cyprus Medical School, Nicosia, Cyprus
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune rheumatic disease characterized by significant vascular abnormalities due to microvascular damage and intimal proliferation in the small arterioles.…
Abstract Number: 0787 • ACR Convergence 2023
Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry
Kristina Clark¹, Shiwen Xu², Voon Ong³, Christopher Buckley⁴ and Christopher Denton², ¹Barts Health NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: We previously described distinct migratory and resident fibroblast populations from lesional skin biopsies in SSc patients. Both populations are profibrotic compared with those from…
Abstract Number: 0948 • ACR Convergence 2023
Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)
Noelle Kosarek¹, Tamar Abel², Sasha Shenk³, Tammara Wood², Jonathan Garlick⁴, Patricia Pioli⁵ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Tufts University, Boston, MA, ⁴Tufts University School of Dental Medicine, Boston, MA, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs. While the tyrosine kinase inhibitor Nintedanib is…
Abstract Number: 1515 • ACR Convergence 2023
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Dinesh Khanna¹, Christopher Denton², Masataka Kuwana³, Daniel Furst⁴, Suiyuan Huang¹, Barbara White⁵ and Robert Spiera⁶, ¹University of Michigan, Ann Arbor, MI, ²University College London, London, United Kingdom, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴University of California Los Angeles, Los Angeles, CA, ⁵SFJ Pharmaceuticals, Towson, MD, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…
Abstract Number: 1668 • ACR Convergence 2023
Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes
Monica Yang¹, Fred Deiter¹, Emily Flynn¹, Jessica Neely¹, Seoyeon Lee², John Greenland¹, Marina Sirota³ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Interstitial lung disease (ILD) is present in up to 90% of patients with systemic sclerosis (SSc) and the leading cause of SSc-related mortality. SSc-ILD…
Abstract Number: 2361 • ACR Convergence 2023
Optimal Combination of Circulating Biomarkers for Predicting the Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis
Keina Yomono¹, Dinesh Khanna² and Masataka Kuwana³, ¹Nippon Medical School University, Tokyo, Japan, ²University of Michigan, Ann Arbor, MI, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: In patients with systemic sclerosis (SSc), progression of interstitial lung disease (ILD) is associated with an increased mortality. Since the course of SSc-ILD is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.